News Hub | News Direct

Doceree launches The NEXT Marketing Lab – a data innovation opportunity for pharma marketers – at Digital Pharma East 2023

Doceree Inc

Doceree, a global platform building unprecedented solutions for HCP programmatic marketing with proprietary data tools, today announced yet another pathbreaking measure for the life sciences industry, The NEXT Marketing Lab. The innovation lab dedicates itself to addressing one of the most pressing challenges in the pharmaceutical sector: data intricacies, especially rigid data silos, that hinder commercial team collaboration, informed decision-making, next-gen research and clinical transformation. Curated for Doceree clients, who will gain exclusive access to the solution, The NEXT Marketing Lab will use proprietary cross-functional collaboration methodologies to identify tailored, next generation data strategies and solutions that maximize outcomes. As a well-known global pharma tech company built around proprietary technology and data tools, Doceree aims to revolutionize data solutions that marketing, sales and access teams can use to plan, deliver, and scale HCP communications backed by timely actionable insights. “The pharma landscape has evolved drastically with the industry waking up to the new reality of digital and incorporating the same into its fold to target HCPs across online platforms. The new scenario is a lot different from how data was traditionally collected in a controlled manner. The digital push has led to innumerable, vast and unstructured HCP datasets that are difficult to exploit for valuable insights that can drive key business decisions to make HCP communications more effective in terms of precision, timing and relevancy,” said Harshit Jain MD, Founder & Global CEO, Doceree. “We are guided by the vision of transforming the pharma messaging landscape. It is with this intent we have launched our latest initiative to break big data silos and bring value to pharma marketing by structuring scattered datapoints. As opposed to how unreal big data in the pharma sector may have looked, it is now a reality the industry can’t escape, and its potential can’t be ignored. The lab will greatly facilitate marketers to use and share data with ease and work with HCP datasets holistically to enhance internal and external collaborations to support innovation. This is the kind of value creation we aim to make for our partners as we assist them in their business growth.” Backed by a team of experts with extensive experience in pharmaceutical marketing, medical, consulting, data science, and technology, Doceree will engage with life sciences companies to explore and customize data strategies and solutions that align to their unique needs. The NEXT Marketing Lab collaborations can be tailored to tackle diverse challenges, such as cross-functional insight sharing, reliable HCP behavior modeling, physician-level personalization and compliant RWD integration. Cross-functional collaboration executed within a well-designed process is key to unlocking change. The NEXT Marketing Lab will use Doceree’s proprietary 4D™ methodology to: Decipher the most pressing commercial challenges impacted by data limitations. Decode relevant and viable data solutions. Decide what to prioritize based on impact and feasibility. Deliver a phased roadmap to achieve goals. “Doceree’s The NEXT Marketing Lab is designed to help marketers not only explore transformational data opportunities, but also to cross the chasm between innovative ideas and impactful market solutions,” said Kate Miller, Executive Vice President of Strategy at Doceree. “At Doceree, our mission is to push how data and technology can enhance the digital experience for the benefit of healthcare providers and their patients. The NEXT Marketing Lab is a significant milestone in fulfilling this vision.” For inquiries about Doceree’s The NEXT Marketing Lab, please contact partner@doceree.com Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs and transparent marketing campaign metrics at scale. To learn more, visit doceree.com. Contact Details Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Company Website https://doceree.com/us/

September 12, 2023 07:42 AM Eastern Daylight Time

Image

Unleashing Pet Industry Trends to Keep Your Furry Friend Healthy, Happy & Pampered

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/Z2YHiW3ehKw Pets are undeniably cherished members of our families and ensuring their happiness, health and comfort is a top priority. In today's world, our furry, feathered, and scaly companions live the good life alongside us, and we strive to provide them with the very best—from their favorite treats to specialized diets, stylish collars, interactive toys and even high-tech gadgets. But what's the next big thing for your beloved pet? That's where SUPERZOO comes in, the pet industry's premier retail event that sets the stage for the latest trends and groundbreaking new products ready to elevate your pet's lifestyle to new heights! With pet spending on the rise, the range of trending products is ever-expanding—from pet health solutions and grooming tools to groundbreaking advancements featuring automation and artificial intelligence, the possibilities to enhance your pet's life are endless. A nationwide media tour was conducted to discuss these topics and more live from the Mandalay Bay Convention Center in Las Vegas, where SUPERZOO took center stage. Organized by the World Pet Association, SUPERZOO is the pet industry’s largest and most comprehensive pet retail event in North America. Topics that were discussed during the media tour included: The latest pet product news and industry insights live from SUPERZOO Pet products that will be hitting retail shelves later this year How technology is taking pet care to the next level What’s next in pet health and wellness trends, including unique foods and diets, specialized supplements, creative habitats and more For more information, visit www.SUPERZOO.org Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 11, 2023 02:15 PM Eastern Daylight Time

Video

News Release

Nevis Brands announces big expansion of Major brand in Nevada

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to share significant news regarding the company's expansion in the cannabis market. Kueber announced that Nevis Brands has successfully secured an agreement with Silver State Wellness, a move that enables them to produce and distribute their product, Major, to cannabis retailers in Nevada. This achievement marks a pivotal step in Nevis Brands' growth strategy. Kueber went on to discuss the production and availability timeline for Major in Nevada. The company is actively working to produce Major, with plans to make it available for sale in cannabis retail stores across Nevada by September 2023. Major, a dosable cannabis beverage with 100mg of THC, is designed to deliver the effects of cannabis consumption within a relatively short time frame of 10-20 minutes. Additionally, Kueber highlighted the expansion of Major's market presence, noting that it has grown from being available in five states to now covering six states. The beverage will come in five different flavors: Sunset Pink Lemonade, Pacific Blue Raspberry, Sacred Grape, Volcanic Orange Mango, and Passionfruit. With its unique dosing mechanism and rapid onset of effects, Major aims to offer consumers an accessible and enjoyable cannabis consumption experience. The collaboration between Nevis Brands and Silver State Wellness opens up new opportunities for the distribution and sale of Major in the Nevada cannabis market. As Nevis Brands continues to expand its reach and product offerings, this latest development showcases its commitment to delivering innovative cannabis products to consumers. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

September 07, 2023 12:53 PM Eastern Daylight Time

Video

Upcoming Phase 2 Data Expected For Longeveron’s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer’s Sector – What To Look For

LONGEVERON INC.

By David Willey, Benzinga Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™ cellular drug in the next 3 to 4 months. Longeveron’s primary drug candidate, a cell-based medicine, is being tested for several indications, including Aging-related Frailty, a rare pediatric disease called hypoplastic left heart syndrome (HLHS), and Alzheimer’s disease (AD). It is running phase 2 trials for each of these conditions and expects to announce top-line results for the AD trial soon. A previous clinical study indicated that Lomecel-B’s™ mechanisms of action (MoA) had the potential to affect multiple AD markers simultaneously, such as reducing neuroinflammation, improving neural blood vessels, and decreasing the brain damage that comes from AD. According to Longeveron, other potential therapies being tested mainly target amyloid plaques or neurofibrillary tangles. Longeveron uses medicinal signaling cells (MSCs) that may cross the blood-brain barrier (based on results from animal studies) and are primarily aimed at downregulating inflammation, which is a pathway associated with AD’s neurodegeneration, including memory loss. Longeveron completed a randomized, placebo-controlled phase 1 trial that tested for safety as a primary objective, as well as potential efficacy. The trial saw no serious adverse events and indicated a statistically significant improvement in cognition in the patients. Importantly, the trial showed that Lomecel-B™ did not appear to cause ARIA (Alzheimer’s Related Imaging Abnormality), a serious potential side effect of some AD treatments. These results led to Longeveron initiating a phase 2 trial late in 2022, a 41-week trial on 48 patients with mild AD. The primary objective for the trial is safety, though the Company is exploring signals for multiple secondary endpoints, including cognitive measures, the AD assessment scale for cognitive function (ADAS-Cog), and inflammatory biomarkers. In addition, the trial is also designed to test whether repeat dosing of Lomecel-B™ may produce greater drug efficacy. The Company anticipates that if the trial is successful and shows efficacy, there is the potential for Lomecel-B™ to be developed as a disease-modifying treatment for AD. Longeveron’s Position In An Active Market By developing Lomecel-B™ as a potential treatment for AD, Longeveron is positioning itself for potential success in a growing sector. With over 6 million Americans suffering from AD in 2021, there is a drive in the pharmaceutical sector to develop a range of treatments for the disease. Multiple companies are currently attempting to develop treatments, while others have received accelerated approval for their drugs from the FDA. The global market for Alzheimer’s Disease therapies was worth $4.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of about 20% from 2023 to 2030. In 2021, Biogen Inc. (NASDAQ: BIIB) received accelerated approval from the FDA for its drug Aducanumab. Acumen Pharmaceuticals (NASDAQ: ABOS) has completed a phase 1 trial for the drug ACU193, and Tiziana Life Sciences (NASDAQ: TLSA) has filed an investigational new drug (IND) application for its drug, Foralumab, for its AD indications. Follow developments from Longeveron’s cell-based therapies on its website. We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions.Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. Forward-Looking StatementsCertain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management's current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as "believe," "expects," "may," "looks to," "will," "should," "plan," "intend," "on condition," "target," "see," "potential," "estimates," "preliminary," or "anticipates" or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur at all, or that any such transaction will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company's results and forward-looking statements are disclosed in the Company's filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 14, 2023. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 844-470-2550 christine@tradigitalir.com Company Website https://longeveron.com/

September 07, 2023 09:25 AM Eastern Daylight Time

Quantum Software Leader Classiq Expands to Boston, Relocates Key Executive to Build Out North American Presence

Classiq Technologies

Classiq Technologies, a leading quantum computing software company, today announced its expansion into the Boston area and the relocation of Shai Lev, vice president of strategic partnerships, to lead the company's growth in North America. Headquartered in Tel Aviv, Classiq has seen rapid growth over the past year as demand increases for its quantum computing software. The company's expansion into Boston enables it to tap into the region's bustling quantum ecosystem, renowned academic institutions and key industries pursuing quantum applications. "As we continue our impressive momentum helping organizations develop real-world quantum applications, Boston is a clear choice for further expansion," said Nir Minerbi, CEO and co-founder of Classiq. "The Boston area is a hub for quantum research and education with an incredible pool of quantum talent. Industries aggressively exploring quantum's potential, such as financial services, pharmaceuticals and healthcare, are very strong there." Lev has been instrumental in forging partnerships with leading quantum hardware and software companies. To lead Classiq’s North America expansion, he relocated and will open the company's Boston-area office. "Boston has one of the highest concentrations of quantum activity today – from research at MIT, Harvard and other universities, to government-funded programs and private-sector efforts," said Lev. "It’s exciting to represent Classiq in the Boston ecosystem and throughout North America as we introduce more organizations to our technologies and products to accelerate their journey to quantum advantage." About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing software platform with a single point of entry into quantum computing, from algorithm design to execution. Tailored to all levels of developer proficiency, Classiq aims to democratize access to quantum computing with software that equips customers to take full advantage of the quantum computing revolution. A low-code development environment ensures that a broader range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of how to program quantum computer hardware. Backed by powerful investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking software development platform. Follow Classiq on LinkedIn, X (formerly Twitter), or YouTube, or visit www.classiq.io to learn more. Contact Details Rainier Communications Michelle Allard McMahon/Jenna Beaucage classiqPR@rainierco.com Company Website http://www.classiq.io/

September 06, 2023 08:05 AM Eastern Daylight Time

Newport Beach Plastic Surgeons Dr. Joseph Cerni and Dr. Nadir Qazi Sued for Fraud and Retention of Stolen Property

Stone LLP

Karen A. Sunday & Associates Inc., a well-regarded commercial real estate broker, recently filed a multi-count lawsuit against Dr. Joseph S. Cerni and Dr. Nadir Qazi, along with their affiliated medical practices and others, for failing to pay, and unlawfully withholding, an earned real estate commission. The lawsuit alleges fraud, breach of contract and unlawful retention of stolen property, among other counts. According to the lawsuit, in May 2022, Dr. Nadir Qazi reached out to Karen Sunday, President of Karen A. Sunday & Associates, seeking her expertise to acquire a building for his Newport Beach cosmetic surgery practice, the Qazi Cosmetic Center. Responding quickly, Sunday reached out to one of her long-time clients, well-known Newport Beach plastic surgeon, Dr. Joseph S. Cerni, owner of Forever Ageless in Newport Beach, inquiring about his interest in selling his office to Qazi. According to court documents, in July 2022, Sunday sent a binding letter of intent to both doctors for the sale of the building, located at 20271 Southwest Birch Street, Suite 100, in Newport Beach with a sale price of $4.75 million. The lawsuit contains various transactional details, including the purchase price, deposit contingencies, escrow conditions, and most crucially, the broker commission. As part of the agreement, Sunday was set to receive a 4% commission from Cerni. Additionally, Court documents allege Qazi was to pay an additional 2% commission for his participation in the transaction. Neither Cerni nor Qazi ever paid for the brokerage services rendered by Sunday and instead aided and abetted each other by unlawfully withholding Sunday’s earned commission. According to the complaint on file in Orange County Superior Court, when the sale closed in December 2022, both Dr. Cerni and Dr. Qazi reneged on their commitment, denying Sunday her rightfully earned commission totaling $285,000. The lawsuit sheds light on the doctors’ intentional deceit, alleging they misled Sunday with a promise to pay their respective commissions to Sunday upon the close of escrow yet failed to do so. The lawsuit seeks damages of no less than $4 million, citing California’s fraud statute in addition to the breach of contract claims. Sunday is represented by Elliott H. Stone, Esq., of Stone LLP, in Irvine California. The lawsuit names among the defendants: Joseph S. Cerni, D.O. a Professional Corporation, JSC Holdings LLC, Rockitgram LLC, Belle Vie Wellness and Medical Aesthetics Inc., Beautiful Reflections Inc., Forever Ageless, Inc., Nubella Med Spa, Inc., Pure Fix Medical Institute, Inc., Qazcorp, Qazi Cosmetic and Monumental Investments LLC. Karen Sunday & Associates, Inc., is a commercial real estate broker specializing in both Tenant and Landlord Representation headquartered in Newport Beach, California. Karen’s expertise is in the leasing and sales of office, industrial, and retail real estate in Southern California. More information at karensunday.com. Stone LLP is a law firm that represents businesses throughout California in complex litigation involving business, construction, real estate, and employment disputes. Download a copy of the lawsuit here and at LawsuitPressRelease.com. Contact Details LawsuitPressRelease.com John P. David +1 888-859-6637 john@LawsuitPressRelease.com Company Website https://stonellp.com/

September 05, 2023 11:16 AM Pacific Daylight Time

News Release

Filament Health takes major step forward entering into licensing agreement with Reset Pharma

Filament Health Corp

Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to announce a significant licensing agreement between Filament Health and Reset Pharmaceuticals. The agreement involves the licensing of Filament Health's proprietary botanical psilocybin drug candidate, known as PEX010, and its associated intellectual property to Reset Pharmaceuticals. The purpose of this partnership is to conduct a phase 2 clinical trial for the treatment of demoralization syndrome. Lightburn explained to Proactive that PEX010 is formulated as an oral capsule and is currently being tested in various phase 1 and phase 2 human clinical trials approved by the US Food and Drug Administration and Health Canada. Demoralization syndrome is a clinically significant condition that affects around 20% of patients with life-altering cancer. This syndrome often presents independently of other mood disorders like depression or anxiety. The licensing agreement with Reset Pharmaceuticals aligns with their goal of developing a psilocybin-related product specifically aimed at treating demoralization syndrome in patients with cancer. By leveraging Filament Health's proprietary botanical psilocybin drug candidate, Reset Pharma aims to contribute to addressing the mental and emotional well-being of patients facing serious medical challenges. This collaboration underscores the growing interest and research into the potential therapeutic applications of psilocybin and highlights Filament Health's commitment to advancing innovative solutions to improve patients' quality of life in the field of mental health and oncology. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 05, 2023 12:29 PM Eastern Daylight Time

Video

hVIVO Canary Wharf move to deliver material increase in capacity - Proactive Research Analyst

hVIVO PLC

Proactive research analyst Daniel Appiah speaks to Thomas Warner at the London studio about his latest report into specialist contract research organisation hVIVO. hVIVO is expanding its presence by establishing a cutting-edge facility at the Canary Wharf Life Sciences Hub in London. The expansion, primarily funded by its clients, will feature state-of-the-art amenities, including quarantine rooms, laboratories, outpatient facilities, and corporate offices all under one roof. Notably, the new site will initially offer 50 quarantine beds, with plans to expand to 70, significantly surpassing the current Whitechapel and Queen Mary facilities, which can accommodate only 43. The move enables hVIVO to conduct simultaneous challenge trials for various clients, enhancing efficiency and increasing revenue. hVIVO's H1 results showcased a remarkable 52% YoY revenue increase to approximately £27.3 million, driven by the growth of their challenge trial order book. With a strong cash position and a prepayment model, the company appears set to meet its 2023 revenue guidance of £53 million with an EBITDA between 15% and 90%. For more details, you can read Daniel's comprehensive report by following the link in the corner. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 05, 2023 08:42 AM Eastern Daylight Time

Video

Tissue Regenix Group says "disciplined approach" paying off at half-year stage

Tissue Regenix Group PLC

Tissue Regenix Group PLC (AIM:TRX) chief executive Danny Lee and chief financial officer David Cocke speak to Thomas Warner from Proactive London after the regenerative medicine company released its interim results for the first six months of 2023. Cocke reports that the company reported a remarkable 19% growth, marking the sixth consecutive period of growth since the pandemic's onset. Their BioRinse and T-cell segments demonstrated substantial growth, with the former up by 20% and the latter by 29%. Gross profit increased to 49%, owing to efficiency gains from their Phase One expansion. He suggests that the company's growth strategy, driven by a "disciplined approach" to supply, sales revenue, sustainability, and scale, has been fundamental to their success. Lee also discusses the launch of a new product under the BioRinse brand, focused on producing safe, sterile tissue for sports medicine applications in the lucrative US market, estimated at approximately $300 million. The new product will primarily be used for tendon and ligament repairs in joints like the knee, ankle and elbow. Looking ahead, the company remains committed to continued growth, both in their core business and expansion into new markets, such as the United States. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 05, 2023 08:37 AM Eastern Daylight Time

Video

Healthcare

Doceree launches The NEXT Marketing Lab – a data innovation opportunity for pharma marketers – at Digital Pharma East 2023

Unleashing Pet Industry Trends to Keep Your Furry Friend Healthy, Happy & Pampered

Nevis Brands announces big expansion of Major brand in Nevada

Upcoming Phase 2 Data Expected For Longeveron’s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer’s Sector – What To Look For

Quantum Software Leader Classiq Expands to Boston, Relocates Key Executive to Build Out North American Presence

Newport Beach Plastic Surgeons Dr. Joseph Cerni and Dr. Nadir Qazi Sued for Fraud and Retention of Stolen Property

Filament Health takes major step forward entering into licensing agreement with Reset Pharma

hVIVO Canary Wharf move to deliver material increase in capacity - Proactive Research Analyst

Tissue Regenix Group says "disciplined approach" paying off at half-year stage